Kornimate/medical-research-clean huggingface dataset:
effects of functional training by high intensity intervals in older adults with mild cognitive impairment.

Conditions: Quality of Life; Aging

Summary: to analyze the effects of a high intensity interval functional training program (hift), in the cognitive and functional capacities of colombian older adults with mild cognitive impairment.

this is a randomized clinical trial of single-blind with 2 arms (control group and experimental group), in which a pre-treatment-postest design has been used. the study will define two groups: a control group (cg) that will not be submitted to treatment, which will be evaluated in the pre and post phase of the study. participants assigned to this group will receive general advice on the positive effects of regular physical activity and will be given a guide to recommendations for promoting physical activity. an experimental group (ge) that after an initial evaluation will undergo a physical training program based on high intensity interval functional training exercises. once the intervention is finished, it will be submitted to a final evaluation to see if there is a difference or not with the results obtained at the beginning.

Eligibility criteria:
inclusion criteria: * more than 60 years * adults with mild cognitive impairment * not participating in any physical exercise program * sufficient physical autonomy to participate in the physical activities required by the study * have no signs of dementia (\<26 on moca) * be able to understand instructions, programs and protocols. exclusion criteria: * contraindications for conducting physical tests * diseases that limit cognitive performance and physical activity.
the effects of sirolimus in patients with dilated cardiomyopathy infected with kaposi sarcoma-associated virus

Conditions: Dilated Cardiomyopathy; Kaposi's Sarcoma-Associated Herpesvirus Infection

Summary: evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with kaposi sarcoma-associated virus -- a multicenter randomized controlled study.

dilated cardiomyopathy (dcm), defined as left ventricular or biventricular dilation and systolic dysfunction in the absence of either pressure or volume overload or coronary artery disease sufficient to explain the dysfunction, is associated with poor cardiovascular outcome and poor prognosis. inflammation, activated by viral persistence, was considered as a key trigger factor of cardiac remodeling and thereby the development of dcm. as a risk factor for dcm, kaposi's sarcoma-associated herpes virus (kshv) inhibits the type i ifn signaling pathway and thereby aggravates known cardiotropic viruses-induced cardiac dysfunction and inflammatory infiltration. activated mtor signaling pathway is a typical feature of kshv-infected cells, which is the most effective therapeutic target of diseases caused by kshv infection. sirolimus, a mtor inhibitor, is a drug that can effectively treat the kshv-infected diseases and suppresses the replication of kshv.therefore, multicenter large randomized controlled trials are needed to verify the efficacy of sirolimus on patients with dcm infected with kshv. this study aimed to evaluate the effiects of sirolimus on the clinical outcomes of patients with dcm infected with kshv and provide theoretical evidence for the clinical application of sirolimus in these patients.

Eligibility criteria:
inclusion criteria: * 18 to 70 years of age; * diagnosed as dilated cardiomyopathy. specifically, (i) left ventricular ejection fraction \ 2 sd) and/or fractional shortening \ 2 sd), as ascertained by echocardiography, radionuclide scanning, or cardiac magnetic resonance imaging; (ii) left ventricular end-diastolic diameter \>117% of the predicted value corrected for age and body surface area (henry's formula), which corresponds to 2 sd of the predicted normal limit +5%; and (iii) in the absence of severe coronary artery disease or valvular disease. * kshv dna seropositivity; * patients are voluntary and signed informed consent. exclusion criteria: * allergic to rapamycin or its derivatives； * the proportion of neutrophils less than 0.5\*10\^9/l or platelet less than 2.5\*10\^10/l; * pregnant women or plan to; * participate in any drug clinical trials within 3 months; * serious neurological disease (alzheimer's disease, parkinson syndrome, progressive lower limbs or deaf patients); * previous history of cancer or tumor, or pathological examination confirmed precancerous lesions; * patients were not optimally managed.
comparing bioavailability when preservative-free makena® (hydroxyprogesterone caproate injection, 250 mg/ml) is administered as an intramuscular manual injection or as a subcutaneous injection using an auto-injector in healthy post-menopausal women

Conditions: Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women

Summary: to demonstrate that a single dose of makena® delivered sq via auto-injector has comparable bioavailability to a single im injection of makena®.


Eligibility criteria:
inclusion criteria: 1. naturally or surgically postmenopausal women, with or without an intact uterus, aged 50 to 75 years of age, inclusive. fsh levels greater than 40 miu/ml exclusion criteria: 1. currently taking any estrogen/progesterone hormone replacement therapy (hrt). 2. history of allergy or sensitivity to hydroxyprogesterone caproate, castor oil or any of the constituents of the study medications, or history of any drug hypersensitivity or intolerance 3. poorly controlled diabetes. 4. history or current evidence of deep vein thrombosis, pulmonary embolism or arterial thromboembolic disease (e.g., stroke, myocardial infarction). 5. known, suspected, or current history of carcinoma of the breast. 6. subjects with a past history of breast cancer on aromatase inhibitors or selective estrogen receptor modulators. 7. known, suspected, or current history of hormone dependent tumor within the last 5 years. 8. any current or recent (within previous 12 months) genital bleeding of unknown etiology. 9. receipt of any investigational drug within 30 days. 10. receipt of any prescription or otc medications that are known to alter cyp3a4 or cyp3a5 levels (e.g., carbamazepine, st. john's wort, ketoconazole, rifampin, ritonavir, alprazolam, azithromycin, loratadine, etc.) within 14. 11. any estrogen, progestin, or selective estrogen receptor modulator (serm) treatment within specified time windows before the study start, ranging from 2 to 6 months. 12. high blood pressure at the screening evaluation, defined as systolic blood pressure \> 150 mm hg or diastolic blood pressure \> 90 mm hg. 13. history of excessive alcohol consumption (on average more than 14 units of alcohol/week) during the past 12 months. 14. use of tobacco products within 30 days of the start of the study.
s8809-s9800-s9911tm- biological markers in patients with follicular lymphoma treated on clinical trial swog-8809, swog-9800, or swog-9911

Conditions: Lymphoma

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict how patients respond to treatment. purpose: this laboratory study is examining biological markers in patients with follicular lymphoma treated on clinical trial swog-8809, swog-9800, or swog-9911.

objectives: * determine the prognostic significance of mum-1, lymphoma-associated macrophages, and regulatory t cells in patients with follicular lymphoma treated on clinical trials swog-8809, swog-9800, or swog-9911 representing pre- and post-monoclonal antibody therapy protocols. * determine whether these factors have similar prognostic significance in patients treated with chemotherapy alone vs chemotherapy and monoclonal antibody therapy on these clinical trials. outline: this is a multicenter study. previously collected tissue samples from patients are analyzed by immunohistochemistry, gene expression profiling, and quantitative analysis for mum1 expression, lymphoma-associated macrophages, foxp3-positive regulatory t cells, cd68, and cd163. projected accrual: a total of 318 samples will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of follicular lymphoma * previously treated on any of the following clinical trials: * swog-8809 * swog-9800 * swog-9911 patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: contiguous stage ii grade 1 follicular lymphoma contiguous stage ii grade 2 follicular lymphoma contiguous stage ii grade 3 follicular lymphoma noncontiguous stage ii grade 1 follicular lymphoma noncontiguous stage ii grade 2 follicular lymphoma noncontiguous stage ii grade 3 follicular lymphoma stage iii grade 1 follicular lymphoma stage iii grade 2 follicular lymphoma stage iii grade 3 follicular lymphoma stage iv grade 1 follicular lymphoma stage iv grade 2 follicular lymphoma stage iv grade 3 follicular lymphoma
modified shell technique versus onlay bone graft in anterior maxilla

Conditions: Implant Complication

Summary: amount of bone volume and (width and height): will be measured using linear measurements from cbct after 6 month from implant insertion. will be measured using histometric analysis of bone area percent sampling from recipient site after 6 months.

augmentation of insufficient bone volume can be brought about by different methods, including, particulate and block grafting materials, guided bone regeneration with or without growth and differentiation factors, ridge splitting, expansion and distraction osteogenesis, either alone or in combination. these techniques may be used for horizontal/vertical ridge augmentation autograft is considered as the gold standard for bone transplantation and various studies have shown efficacy for it. it is osteogenic, osteoconductive and osteoinductive. autografts can be derived from extra oral source (iliac crest, ribs) or intraoral source (chin, ramus). they can be used in block or particulate form. corticocancellous block grafts are preferred because of enhanced revascularization of the cancellous portion, and mechanical support and rigidity of the cortical portion, which ensures optimal ridge augmentation. fouad khoury presented a three-dimensional (3d) reconstruction technique for atrophic ridges and complicated vertical bone defects using mandibular bone block graft "the gold standard". there are several possibilities for augmentation of bone volume depending on situation, indication and adequate diagnosis; the treatment options can be extended from minimally invasive procedures with locally harvested bone grafts in local anesthesia, to very sophisticated grafting techniques for 3d bone reconstruction with extra oral harvested bone grafts. khoury reported that his ascending ramus grafts is almost 5 times more than chin grafts

Eligibility criteria:
inclusion criteria: * patients with atrophic anterior maxilla * no intraoral soft and hard tissue pathology * no systemic condition that contraindicate implant placement * both sexes. exclusion criteria: * heavy smokers more than 20 cigarettes per day. * patients with systemic disease that may affect normal healing. * psychiatric problems * immunodeficiency pathology, bruxism, stress situation (socially or professionally), emotional instability, and unrealistic aesthetic demands.

Keywords: anterior augmentation,shell technique,onlay bone graft
safety, efficacy and pharmacokinetics of an antifungal in patients undergoing chemotherapy

Conditions: Acute Myeloid Leukemia

Summary: patients who undergo chemotherapy for leukemia will receive study medication for prevention of fungal infections. the study investigates the safety and tolerability of two different dosages, the efficacy in prevention of fungal diseases.

patients with acute myeloid leukemia who undergo aggressive chemotherapy are due to immunosuppression susceptible to infections, including fungal infections. as the failure rate in the treatment of invasive fungal infections is high, prophylaxis is frequently recommended. this open label study investigates the safety and tolerability of two different dosages of a water soluble azole antifungal, as well as the efficacy in prevention of invasive fungal infections and pharmacokinetic data.

Eligibility criteria:
inclusion criteria: * diagnosis of acute myeloid leukemia * patients entering first induction treatment; or subsequent chemotherapy if no prior invasive fungal infection was observed * expected to be neutropenic for \>9 and \<28 days after enrollment * women of childbearing potential must have a negative pregnancy test exclusion criteria: * patients who received any systemic antifungal therapy for more than 72 hours prior to first administration of study medication. topical polyenes or nystatin are acceptable but should be discontinued during the study * patients who received systemic antifungal therapy for proven or probable fungal infection in the last 12 months * patients with fever defined as central body temperature of \> 38°c * known hypersensitivity to azoles or any component of the study medication * concomitant use of rifampicin, rifabutin, ergots alkaloids, terfenadine, astemizole, cisapride, pimozide, quinidine, long acting barbiturates, neostigmine, and carbamazepine * hepatic or severe renal dysfunction * patients with a medical history of oliguria unresponsive to fluid challenge * patients with a concomitant medical condition that may be an unacceptable additional risk to the patient should he/she participate in the study * treatment with any investigational drug within 30 days prior to the first administration of study medication except open label chemotherapy protocols * suspected other or additional cause for neutropenia or immunosuppression

Keywords: isavuconazole bal8557 asp9766 chemotherapy prophylaxis systemic fungal infection
function magnetic resonance imaging to assess two therapeutic strategies in multiple sclerosis (neurorehem).

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is an autoimmune disease that causes cognitive and motor disabilities and contributes to decrease patients life quality. previous results described that there are some ms patients that showed (at least in some phases of the disease) neuroplasticity processes that are able to compensate some cognitive deficits. moreover, neuroplasticity processes seem to be limited and related to the degree of gray matter atrophy (patients with less atrophy show grater neuroplasticity than those with higher atrophy level). the aims of this project are: 1. to study behavioral changes (post-training) induced by two different rehabilitation programs: a)cognitive training focused on exclusively enhancing working memory and b) aerobic + cognitive training aimed to enhance attention, working memory processes and motor capabilities using a virtual reality game. 2. to study neuroplasticity changes (post-training functional connectivity changes) induced by these rehabilitation programs 3. to observe the role of the atrophy in brain neuroplasticity processes. neuropathological status and neuroplasticity processes (studied using neuroimaging tools) as well as cognitive performance using neuropsychological tools will be assessed in a group of ms patients (with different phenotypes) at two different time points: before any training (s1) and after 10 days of training (s2). this project will be financed by the ministerio de ciencia, innovación y universidades of the spanish government and also have been approved by the ethical committee of universitat jaume i.


Eligibility criteria:
inclusion criteria: * multiple sclerosis diagnosis. exclusion criteria: * other neurological pathologies comorbidity. * magnetic resonance imaging incompatibilities. * motor impairment degree that impede the task performance.

Keywords: multiple sclerosis magnetic resonance imaging neuroplasticity cognitive impairment virtual reality
the impact of propofol and ketamine on cardiovascular collapse during induction for intubation

Conditions: Cardiovascular Collapse; Intubation Complication; Anaesthetic Complication Cardiac

Summary: this prospective observational study evaluates the impact of propofol and ketamine on the risk of cardiovascular collapse during induction for endotracheal intubation in critically ill patients. induction agents play a crucial role in managing hemodynamic stability, particularly in this vulnerable population. propofol, known for its vasodilatory and myocardial depressant effects, has been associated with significant hypotension during induction. conversely, ketamine, with its sympathomimetic properties, is often considered a safer alternative for hemodynamic stability. in addition to comparing the incidence of cardiovascular collapse-defined as severe hypotension or cardiac arrest-this study examines the relationship between these induction agents and shock indices, including systolic shock index, diastolic shock index, age-adjusted shock index, and modified shock index. these parameters will provide a more detailed understanding of the hemodynamic effects of each agent and their clinical implications. the findings aim to guide induction agent selection to optimize outcomes in critically ill patients.


Eligibility criteria:
inclusion criteria: * patients aged over 18 years * patients admitted to the intensive care unit (icu) who undergo endotracheal intubation during their icu stay will be included. exclusion criteria: * patients who did not provide consent to participate in the study * patients intubated due to cardiac arrest * patients intubated outside the intensive care unit

Keywords: cardiac arrest intubation shock index
sunitinib malate in treating patients with kidney cancer

Conditions: Kidney Cancer

Summary: rationale: sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. purpose: this clinical trial is studying how well sunitinib malate works in treating patients with kidney cancer.

objectives: primary * to determine whether a link exists between the effectiveness of therapy with sunitinib malate and development of blood biomarkers, specifically the angiogenic factors vegf and interleukin-8 (il-8), in patients with kidney cancer. secondary * to evaluate the link between the time to progression and the development of vegf and il-6 cxcl7 and cxck5 blood levels in these patients. * to evaluate the link between vegf and il-6 cxcl7 and cxck5 blood levels and disease-free survival of these patients after 3, 6, 9, and 12 months of treatment. * to evaluate the link between vegf and il-6 cxcl7 and cxck5 blood levels and overall survival of these patients. outline: this is a multicenter study. patients receive oral sunitinib malate once daily on days 1-28. courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. blood samples are collected at baseline and then every 6 weeks for pharmacokinetic analysis.

Eligibility criteria:
disease characteristics: * histologically confirmed renal cell carcinoma * metastatic disease requiring first-line treatment with sunitinib malate * no prior therapy for metastatic disease * no symptomatic or uncontrolled cerebral metastasis patient characteristics: * affiliation to the french social insurance * life expectancy ≥ 3 months * no heart failure * no chronic unstable disease * no long qt interval * no history of another primary cancer * no severe, uncontrolled acute infection * no severe, uncontrolled hypertension * no psychological disorder prior concurrent therapy: * see disease characteristics

Keywords: stage iv renal cell cancer
risk of nephrogenic systemic fibrosis (nsf) in patients with moderate renal insufficiency after the administration of magnevist

Conditions: Fibrosis; Kidney Failure; Renal Insufficiency

Summary: assess potential risk for nsf in subjects with renal impairment (moderate) post magnevist injection. subjects will be screened within 48 hours of previously scheduled mri, those meeting the enrollment criteria will be enrolled prior to mri and followed for 2 years post mri with visits occuring at 1yr and 2 yr timepoints, in addition follow-up phone calls conducted at 1, 3, 6 and 18 months to assess for skin changes suggestive of nsf.


Eligibility criteria:
inclusion criteria: * patients must have moderate (egfr 30-59 ml/min/1.73 m\^2) renal impairment and be scheduled for a contrast enhanced mri with magnevist injection at the recommended dose of 0.1 mmol/kg. exclusion criteria: * gadolinium based contrast agent (other then magnevist) enhanced mri within 12 months prior to administration of magnevist * history of nsf * clinically unstable or age \<2 yrs

Keywords: gadolinium nsf renal impairment chemically induced adverse effects contrast media complications
confocal laser microscopy in non erosive reflux disease

Conditions: Acid Reflux Disease; Heartburn

Summary: heartburn or reflux disease affects about 20% of americans. 50 - 70% of people who have endoscopy for reflux disease have a normal appearing esophagus. confocal laser microscopy allows us to see changes in the cells not visable during routine endoscopy. whe goal of this study is to identify the use of this new technique in diagnosing reflux in patients who have normal appearing esophagus.

gastroesophageal reflux disease (gerd) remains a major problem in the united states affecting about 20% of americans. upper endoscopy (egd) is commonly used to diagnose and grade gerd based on mucosal breaks and erosions. it is now evident from multiple studies however that the majority of gerd patients (50-70%) have negative egds.these patients are refered to as "non erosive reflux disease" (nerd) patients.confocal laser microscopy (clm) is a new endoscopic technique that offers the advantage of detecting histologic changes during real time endoscopy and thus can diagnose nerd. we thus propose to study the sensitivity and specificity of clm in predicting nerd. we hypothesize that clm can reliably diagnose nerd in the appropriate clinical setting based on intrapapillary capillary loop patterns. this will be a pilot study after which a randomized trial will evaluate the reversibility of these changes after ppi therapy as seen by clm

Eligibility criteria:
inclusion criteria: 1. patients 18 years to 85 years old who are referred for an upper endoscopy for symptoms of reflux disease 2. patients who are able to give informed consent exclusion criteria: 1. patients with a history of erosive esophagitis 2. patients with a history of barrett's esophagus 3. patients who on upper endoscopy have any current evidence of erosive esophagitis, barrett's esophagus or varices 4. patients who are unable or unwilling to undergo endoscopic evaluation 5. patients who are unable to give informed consent 6. patients with a known coagulopathy who are unable to be off therapy

Keywords: reflux heartburn